Holen Sie sich die Stockscreener-App
36.64
0.87%
-0.32
Schlusskurs vom Vortag:
$36.96
Offen:
$36.2
24-Stunden-Volumen:
5.63M
Relative Volume:
1.19
Marktkapitalisierung:
$74.78B
Einnahmen:
$40.10B
Nettoeinkommen (Verlust:
$3.26B
KGV:
23.14
EPS:
1.5831
Netto-Cashflow:
$4.57B
1W Leistung:
+1.30%
1M Leistung:
+8.47%
6M Leistung:
-12.45%
1J Leistung:
-12.64%
1-Tages-Spanne:
$36.05
$36.67
1-Wochen-Bereich:
$36.05
$37.22
52-Wochen-Spanne:
$31.71
$45.92
Gsk Plc Adr Stock (GSK) Company Profile
Vergleichen Sie GSK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
36.64 | 74.78B | 40.10B | 3.26B | 4.57B | 1.5831 |
|
LLY
Lilly Eli Co
|
873.68 | 830.35B | 45.04B | 10.59B | 414.30M | 11.71 |
|
NVO
Novo Nordisk Adr
|
88.08 | 390.99B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
ABBV
Abbvie Inc
|
202.08 | 356.74B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
162.30 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
MRK
Merck Co Inc
|
89.50 | 251.88B | 64.17B | 17.12B | 14.84B | 6.7297 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-12 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-11-15 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-11-12 | Herabstufung | Jefferies | Buy → Hold |
| 2024-10-31 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-07-08 | Herabstufung | UBS | Buy → Neutral |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-03-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-02-13 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Fortgesetzt | UBS | Buy |
| 2024-01-03 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-03-17 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2023-02-27 | Fortgesetzt | Goldman | Buy |
| 2023-01-03 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-12-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-11-11 | Herabstufung | UBS | Neutral → Sell |
| 2022-09-15 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2022-09-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-21 | Fortgesetzt | Citigroup | Neutral |
| 2022-02-11 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-11-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2021-06-24 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2021-03-23 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-04 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2021-01-20 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Hold |
| 2020-11-02 | Hochstufung | Liberum | Hold → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-02-12 | Herabstufung | Shore Capital | Hold → Sell |
| 2020-01-16 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2019-12-02 | Eingeleitet | SVB Leerink | Outperform |
| 2019-11-21 | Hochstufung | UBS | Neutral → Buy |
| 2019-10-11 | Hochstufung | Cantor Fitzgerald | Hold → Buy |
| 2019-09-03 | Fortgesetzt | Citigroup | Neutral |
| 2019-09-03 | Hochstufung | Societe Generale | Sell → Buy |
| 2019-08-13 | Fortgesetzt | JP Morgan | Neutral |
| 2019-06-17 | Fortgesetzt | Morgan Stanley | Underweight |
| 2019-03-08 | Herabstufung | Shore Capital | Buy → Hold |
| 2019-02-22 | Herabstufung | UBS | Buy → Neutral |
| 2019-01-14 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2018-12-11 | Fortgesetzt | Jefferies | Buy |
| 2018-10-09 | Eingeleitet | Guggenheim | Neutral |
| 2018-08-30 | Herabstufung | Liberum | Buy → Hold |
| 2018-04-04 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2018-03-22 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-02-09 | Hochstufung | Kepler | Reduce → Hold |
Alle ansehen
Gsk Plc Adr Aktie (GSK) Neueste Nachrichten
April 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against GSK - GlobeNewswire Inc.
Deadline Alert: GSK plc. (GSK) Investors Who Lost Money - GlobeNewswire
Deadline Alert: GSK plc. (GSK) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - TradingView
A closer look at Gold Fields Ltd ADR’s (GFI) current quarter earnings projections - US Post News
Law Offices of Frank R. Cruz Encourages GSK plc. (GSK) Investors To Inquire About Securities Fraud Class Action - Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages GSK plc. (GSK) Investors To Inquire About Securities Fraud Class Action - Business Wire
Is GSK Plc ADR (GSK) worth investing in despite its undervalued state? - US Post News
Chewy Inc (CHWY) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
GSK PLC Stockholder Notice: Shareholder Rights Law Firm - GlobeNewswire
O’Reilly Automotive, Inc [ORLY] stock for 2,179,380 USD was sold by CONN TAMARA F. - Knox Daily
Buying Buzz: GSK Plc ADR [GSK] 10% Owner GSK plc purchases 2,791,930 shares of the company - Knox Daily
Bear Of The Day: GSK PLC (GSK) - Yahoo Finance
MNKD Shares Experience Surge in Value - Knox Daily
Torrid Holdings Inc [CURV] Shares Jump Approximately 29.38% Over the Year - Knox Daily
D-Wave Quantum Inc [QBTS] Records 200-Day SMA of $2.33 - Knox Daily
Rumble Inc [RUM] Records 50-Day SMA of $10.53 - Knox Daily
Investor Alert: Robbins LLP Informs Stockholders of the GSK PLC Class Action - PR Newswire
Rosen Law Firm Urges GSK plc (NYSE: GSK) Investors with Large Losses to Contact the Firm for Information About Their Rights - Business Wire
Wall Street Analyst Downgrade Melco Resorts & Entertainment Ltd ADR [MLCO]. What else is Wall St. saying - The DBT News
GSK Beats on Q4 Earnings & Sales, Stock Up on Raised Long-Term Outlook - Yahoo Finance
For Juniper Networks Inc [JNPR], Analyst sees a rise to $40. What next? - The DBT News
Market Analysts see Apollo Global Management Inc [APO] gaining to $188. Time to buy? - The DBT News
Tuya Inc ADR [TUYA] Revenue clocked in at $280.97 million, up 66.48% YTD: What’s Next? - The DBT News
GSK Plc ADR (GSK) Stock: A Comprehensive 52-Week Review - The InvestChronicle
The Significance of Moving Averages in BridgeBio Pharma Inc Inc. (BBIO) Price Performance - The InvestChronicle
Top investors say GSK Plc ADR (GSK) ticks everything they need - SETE News
GSK share price - GSK
Earnings Preview: GSK (GSK) Q4 Earnings Expected to Decline - Yahoo Finance
Are Investors Keen On Selling Holdings In GSK Plc ADR (NYSE: GSK)? - Stocks Register
Dow Inc (NYSE: DOW) Is A Buzzing Hot Stock - Stocks Register
The 10 Best Companies to Invest in Now - Morningstar
In 2025, GSK Plc ADR (NYSE: GSK) Shares Will Likely Be Bullish - Stocks Register
18 of the Best Stocks and ETFs to Buy Based on 2025 Expert Forecasts - Morningstar
Precidian Investments Builds Out Its ADRhedged ETF Lineup with Four New Strategies, Offering Targeted International Exposure with Integrated Currency Hedge - Business Wire
Gsk Plc ADR (GSK-N) QuotePress Release - The Globe and Mail
Best International Companies to Own: 2025 Edition - Morningstar
FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD - MSN
GSK Stock Declines 20% In 3 Months: Should You Buy, Sell Or Hold? - Barchart
GSK Stock Declines 20% in 3 Months: Should You Buy, Sell or Hold? - Zacks Investment Research
FDA Accepts GSK's Filing For Expanded Use Of Nucala In COPD - Barchart
Finanzdaten der Gsk Plc Adr-Aktie (GSK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.61%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):